{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:04:57Z","timestamp":1789653897176,"version":"4.0.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic therapies have transformed management of severe chronic rhinosinusitis with nasal polyps (CRSwNP), but response variability persists. Baseline biomarkers may identify patients most likely to benefit, yet no marker is validated for routine clinical use. This systematic review evaluated baseline biomarkers predicting clinical and endoscopic response to biologic therapy in adults with CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search identified studies reporting baseline biomarkers and response to biologics (dupilumab, omalizumab, anti-IL-5 agents) in adult CRSwNP. Ten studies with 489 participants met inclusion criteria. Data extraction included biomarker type, thresholds, outcomes [SNOT-22, nasal polyp score (NPS), radiologic scores], and follow-up duration. Random-effects meta-analysis was performed for dichotomized high vs. low baseline eosinophil counts. Certainty of evidence was assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Meta-analysis demonstrated that elevated eosinophils (&amp;gt;300\u2005cells\/\u00b5L or study-defined high) increased odds of SNOT-22 improvement (OR 3.07, 95% CI 2.00\u20134.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%) and \u22651-point NPS reduction (OR 2.83, 95% CI 1.86\u20134.30,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%). Serum IgE and other biomarkers (ECP, cytokine panels, radiologic markers) showed inconsistent associations with response across studies. Certainty of evidence was low to very low due to observational designs, heterogeneity, and imprecision. Funnel plot symmetry and Egger's test (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.36) suggested minimal publication bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence, though limited by low certainty, suggests baseline peripheral eosinophil count is the most consistent predictor of biologic response in CRSwNP. These findings support further investigation of eosinophils as a potential predictive biomarker, but prospective validation is needed before clinical implementation. Other biomarkers showed inconsistent predictive value across studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251251904.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1793335","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:24:12Z","timestamp":1789547052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive biomarkers of biologic therapy response in chronic rhinosinusitis with nasal polyps: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Omair","family":"Al Hussain","sequence":"first","affiliation":[{"name":"Department of Otolaryngology and Head & Neck Surgery, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3810\/pgm.2009.11.2081","article-title":"Diagnosis and management of chronic rhinosinusitis in adults","volume":"121","author":"Marple","year":"2009","journal-title":"Postgrad Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaip.2022.01.016","article-title":"Epidemiology of chronic rhinosinusitis: prevalence and risk factors","volume":"10","author":"Sedaghat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaip.2016.05.004","article-title":"Phenotypes and emerging endotypes of chronic rhinosinusitis","volume":"4","author":"Bachert","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/14712598.2020.1729350","article-title":"Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis","volume":"20","author":"Licari","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B7","volume-title":"New Therapies for Uncontrolled Severe Chronic Rhinosinusitis with Nasal Polyps","author":"De Santis","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/1744666X.2021.1847083","article-title":"Mechanistic insights from targeting IL-4 and IL-13 via IL-4R\u03b1 inhibition with dupilumab in CRSwNP","volume":"16","author":"Kariyawasam","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1042\/CS20190281","article-title":"New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis","volume":"137","author":"Striz","year":"2023","journal-title":"Clin Sci (Lond)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/JAA.S437190","article-title":"Benralizumab in severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: the real-world, multi-country RANS observational study","volume":"17","author":"Le","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/1945892418779451","article-title":"Systemic predictors of eosinophilic chronic rhinosinusitis","volume":"32","author":"Ho","year":"2018","journal-title":"Am J Rhinol Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11882-023-01114-w","article-title":"Type 2 biomarkers for the indication and response to biologics in CRSwNP","volume":"23","author":"Guo","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/jpm12081251","article-title":"Sinonasal biomarkers defining type 2-high and type 2-low inflammation in chronic rhinosinusitis with nasal polyps","volume":"12","author":"De Corso","year":"2022","journal-title":"J Pers Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s12325-025-03120-y","article-title":"Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps","volume":"42","author":"Peters","year":"2025","journal-title":"Adv Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/all.16499","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence","volume":"80","author":"Cai","year":"2025","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.69854\/jcq.2025.0016","article-title":"Biologic agents in the treatment of severe chronic rhinosinusitis with nasal polyps in adults: a systematic review and meta-analysis","volume":"2","author":"Zheng","year":"2025","journal-title":"J Clin Question"},{"key":"B18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14740338.2023.2251382","article-title":"Post-marketing safety of anti-IL-5 monoclonal antibodies: an analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Zou","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40265-024-02037-0","article-title":"Anti-IL-5 pathway agents in eosinophilic-associated disorders across the lifespan","volume":"84","author":"Lombardi","year":"2024","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/19458924251399711","article-title":"Five-item sino-nasal outcome test in evaluation of disease burden in chronic rhinosinusitis with nasal polyps","volume":"40","author":"Wu","year":"2026","journal-title":"Am J Rhinol Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00405-024-08973-7","article-title":"Correlation of sino-nasal outcome test and nasal polyp score in dupilumab-treated chronic rhinosinusitis with nasal polyps","volume":"282","author":"Mauthe","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2158244012470110","article-title":"An individual differences measure of attributions that affect achievement behavior: factor structure and predictive validity of the academic attributional style questionnaire","volume":"2","author":"Higgins","year":"2012","journal-title":"SAGE Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/jcm10040853","article-title":"Predictors and early markers of response to biological therapies in inflammatory bowel diseases","volume":"10","author":"Privitera","year":"2021","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/Lary.31948","article-title":"Clinical effects and response time of biological drugs in CRSwNP: real-life experience","volume":"135","author":"De Santis","year":"2025","journal-title":"Laryngoscope"},{"key":"B28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12325-024-03006-5","article-title":"Effect of tezepelumab on sino-nasal outcome test (SNOT)-22 domain and symptom-specific scores in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps","volume":"42","author":"Jacobs","year":"2025","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.otohns.2007.02.004","article-title":"The Lund-mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?","volume":"137","author":"Hopkins","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2515245919848684","article-title":"Recommendations for increasing the transparency of analysis of preexisting data sets","volume":"2","author":"Weston","year":"2019","journal-title":"Adv Methods Pract Psychol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"i1114","DOI":"10.1136\/bmj.i1114","article-title":"Analysing indicators of performance, satisfaction, or safety using empirical logit transformation","volume":"352","author":"Stevens","year":"2016","journal-title":"Br Med J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4097\/kja.25001","article-title":"Heterogeneity in meta-analyses: an unavoidable challenge","volume":"78","author":"Choi","year":"2025","journal-title":"Korean J Anesthesiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/01621459.1994.10476864","article-title":"Applications of radial plots","volume":"89","author":"Galbraith","year":"1994","journal-title":"J Am Stat Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 biomarkers in CRSwNP","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100702","DOI":"10.1016\/j.waojou.2022.100702","article-title":"Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on noninvasive markers: a real-life prospective study","volume":"15","author":"Zheng","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2500\/aap.2021.42.210058","article-title":"Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis","volume":"42","author":"Patel","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.3390\/jcm11237056","article-title":"Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies: a real-life cohort study","volume":"11","author":"Maza-Solano","year":"2022","journal-title":"J Clin Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s00405-023-08417-8","article-title":"Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study","volume":"281","author":"De Corso","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/jcm13030754","article-title":"Eosinophilic patterns in patients with seasonal allergy affected by bronchial asthma and rhinitis\/rhinosinusitis: efficacy of benralizumab in patients with the persistent pattern","volume":"13","author":"D\u2019Aiuto","year":"2024","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/pharmaceutics16111370","article-title":"Investigation of blood count-based inflammatory biomarkers as predictors of response to dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps","volume":"16","author":"Habenbacher","year":"2024","journal-title":"Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1007\/s00405-024-08574-4","article-title":"The value of biomarkers in CRSwNP with biologicals: long-term dupilumab follow-up","volume":"281","author":"Sarnoch","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3390\/jcm13123575","article-title":"Real-life evidence of mepolizumab treatment in chronic rhinosinusitis with nasal polyps: a multicentric study","volume":"13","author":"Cavaliere","year":"2024","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101009","DOI":"10.1016\/j.waojou.2024.101009","article-title":"Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers","volume":"17","author":"Sima","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/jcm14041079","article-title":"Advances in biologic therapies for allergic diseases: current trends, emerging agents, and future perspectives","volume":"14","author":"Alska","year":"2025","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/biom14050546","article-title":"Roles of IL-4\/IL-13 in eosinophil-predominant severe asthma","volume":"14","author":"Nakagome","year":"2024","journal-title":"Biomolecules"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/all.16620","article-title":"The evolution, immunopathogenesis and biomarkers of type 2 inflammation in common allergic disorders","volume":"80","author":"Gao","year":"2025","journal-title":"Allergy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"120634","DOI":"10.1016\/j.cca.2025.120634","article-title":"Immunoassay-based biomarkers in atopic dermatitis","volume":"579","author":"Orayj","year":"2026","journal-title":"Clin Chim Acta"},{"key":"B50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","article-title":"Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada","volume":"19","author":"Yong","year":"2023","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1793335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:38:34Z","timestamp":1789652314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1793335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":49,"alternative-id":["10.3389\/fmed.2026.1793335"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1793335","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1793335"}}